Cargando…
Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Autores principales: | Sellam, Jérémie, Rivière, Elodie, Courties, Alice, Rouzaire, Paul-Olivier, Tolusso, Barbara, Vital, Edward M., Emery, Paul, Ferracioli, Gianfranco, Soubrier, Martin, Ly, Bineta, Chavez, Houria Hendel, Taoufik, Yassine, Dougados, Maxime, Mariette, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256546/ https://www.ncbi.nlm.nih.gov/pubmed/28115013 http://dx.doi.org/10.1186/s13075-017-1221-4 |
Ejemplares similares
-
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
por: Sellam, Jérémie, et al.
Publicado: (2016) -
Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis
por: Rivière, Elodie, et al.
Publicado: (2018) -
Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sjögren syndrome
por: Dupré, Anastasia, et al.
Publicado: (2021) -
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019) -
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
por: Ferraccioli, Gianfranco, et al.
Publicado: (2016)